Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity

• Status: Completed
• Trial end date: 2021-12-02
• Target enrollment: 0
• Participant gender: Female

Summary

Anthracyclines are one of the most well-known and effective drugs used to treat malignancies.The most important limiting factor in the use of this drug is its cardiac toxicity which includes cardiomyopathy and congestive heart failure. Bisoprlol is a β1-specific β-blocker that can reduce cardiac overload and also have anti-inflammatory antioxidant effects and can reduce reactive oxygen metabolites so it can be used as a cardioprotective agent in patients with a high risk of heart failure. To the best of our knowledge, no study has been performed to evaluate the prophylactic effect of bisoprolol solely in patients under chemotherapy with anthracyclines. This study is aimed to evaluate the cardioprotective role of bisoprolol in patients with non-metastatic breast cancer receiving doxorubicin, by measuring global longitudinal strain before and after treatment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shahid Beheshti University of Medical Sciences
• Treatments: Bisoprolol

Criteria

Inclusion Criteria:

patients that was diagnosed with non-metastatic breast cancer and anthracycline-based chemotherapy were planned for them

Exclusion Criteria:

• Established ischemic heart disease

• Baseline LVEF <50%, cardiomyopathy (restrictive, dilated or hypertrophic) detected by transthoracic echocardiography

• Moderate or severe valvular disease,

• Prior chemotherapy,

• Presence of contraindication for beta-blockers and cardiac arrhythmias and lack of patient compliance

• Patients that had consuming angiotensin converting enzyme Inhibitors, angiotensin receptor Inhibitors,diuretics,statins,other beta-blockers or non-dihydropyridin calcium channel blockers